Discover and read the best of Twitter Threads about #Calcifediol
Most recents (4)
A ciência dos protocolos de tratamento precoce coberto por estudos robustos! Existe muita ciência!
Protocolo da #NITAXOZANIDA ou Annita.
Estudos randomizados mostram 55% ate 78% de diminuição da carga viral em pacientes com 5 dias de tratamento.
pubmed.ncbi.nlm.nih.gov/33361100/
Protocolo da #NITAXOZANIDA ou Annita.
Estudos randomizados mostram 55% ate 78% de diminuição da carga viral em pacientes com 5 dias de tratamento.
pubmed.ncbi.nlm.nih.gov/33361100/
Recomendado em falta de ivermectina uso de NITAXOZANIDA dose de 500mg 8/8 hrs p/ 5 dias em adultos.
*obs: publicação tem fins informativos e não descartam a necessidade de avaliação médica p/ tratamento COVID, todo medicamento pode dar reação adversa.
pubmed.ncbi.nlm.nih.gov/33361100/
*obs: publicação tem fins informativos e não descartam a necessidade de avaliação médica p/ tratamento COVID, todo medicamento pode dar reação adversa.
pubmed.ncbi.nlm.nih.gov/33361100/
Maratona de Estudos 2/15
#Fluvoxamina vs Placebo e deterioração clínica em pacientes ambulatoriais com COVID-19 sintomático: um ensaio clínico randomizado
pubmed.ncbi.nlm.nih.gov/33180097/
#Fluvoxamina vs Placebo e deterioração clínica em pacientes ambulatoriais com COVID-19 sintomático: um ensaio clínico randomizado
pubmed.ncbi.nlm.nih.gov/33180097/
Eigentlich wollte ich zum Thema #VitaminD und #COVID19 nichts mehr schreiben. Zu nervig. Jetzt macht ein neuer #Preprint die Runde. Die Pressemeldungen überschlagen sich schon, ohne die erheblichen Schwachpunkte zu nennen. Ein kleiner Servicetweet. 1/x papers.ssrn.com/sol3/papers.cf… 
Es handelt sich mal wieder um einen sog. #Preprint. Das heißt: Das wissenschaftliche Prüfverfahren des Peer Reviews wurde noch nicht durchlaufen. Peer Review nervt mich auch oft, aber ohne geht’s nicht. Deshalb: Dies sind noch nicht überprüfte Daten! 2/x
Der Titel klingt harmlos, aber das Abstract hat es in sich: 551 zufallsverteilte #COVID19-Patienten haben entweder #Calcifediol (VitaminD3-Vorstufe) oder nichts erhalten (Kontr.). Ergebnis: Aus der Vitamin D-Gruppe starben 36 Patienten (6,5%), aus der Kontrollgruppe 57 (15%). 3/x
1/
Large RCT (n=930) in Barcelona, 🇪🇸: #calcifediol vs control among hospitalized #COVID_19 patients.
Strong clinical benefit: ↘️ICU admission & ↘️mortality.
Unclear to me why this preprint got unnoticed (published three weeks ago) !
#VitaminD
papers.ssrn.com/sol3/papers.cf…
Large RCT (n=930) in Barcelona, 🇪🇸: #calcifediol vs control among hospitalized #COVID_19 patients.
Strong clinical benefit: ↘️ICU admission & ↘️mortality.
Unclear to me why this preprint got unnoticed (published three weeks ago) !
#VitaminD
papers.ssrn.com/sol3/papers.cf…
2/
These new results confirm similar positive results for calcifediol generated in Cordoba in a smaller pilot RCT
These new results confirm similar positive results for calcifediol generated in Cordoba in a smaller pilot RCT
3/
The new study in Barcelona has limitations: no placebo (open label); randomization per ward (not individual); modified intention to treat for some patients.
Yet results are very encouraging !
It was apparently submitted to @TheLancet. I hope it will get published soon.
The new study in Barcelona has limitations: no placebo (open label); randomization per ward (not individual); modified intention to treat for some patients.
Yet results are very encouraging !
It was apparently submitted to @TheLancet. I hope it will get published soon.
Essai clinique randomisé
#VITAMINED
➡️ 76 patients hospitalisés COVID-19,
infection respiratoire aiguë
confirmée par radio + PCR SARS-CoV-2 positive
➡️ Soins standards : hydroxychloroquine + azithromycine
1/3
ncbi.nlm.nih.gov/pmc/articles/P…
#VITAMINED
➡️ 76 patients hospitalisés COVID-19,
infection respiratoire aiguë
confirmée par radio + PCR SARS-CoV-2 positive
➡️ Soins standards : hydroxychloroquine + azithromycine
1/3
ncbi.nlm.nih.gov/pmc/articles/P…
✅ Groupe traitement (50) #Calcifediol (VITAMINE D)
➡️ 1 admission en l'USI (2%),
✅ Groupe témoin (26) :
➡️ 13 admissions en USI (50%)
✅ Risque multivarié Odds Ratio pour USI (Calcifediol versus Sans traitement Calcifediol)
➡️ 0,03 (IC à 95%: 0,003-0,25).
2/3
➡️ 1 admission en l'USI (2%),
✅ Groupe témoin (26) :
➡️ 13 admissions en USI (50%)
✅ Risque multivarié Odds Ratio pour USI (Calcifediol versus Sans traitement Calcifediol)
➡️ 0,03 (IC à 95%: 0,003-0,25).
2/3
✅ Aucun des patients traités par Calcifediol n'est décédé et tous ont été libérés sans complication.
✅ Sur les 13 patients admis à l'USI du groupe témoin
➡️ 2 décès
3/3
✅ Sur les 13 patients admis à l'USI du groupe témoin
➡️ 2 décès
3/3
